NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Sell
2
BCYC Quote, Financials, Valuation and Earnings
Last price:
$14.60
Seasonality move
:
10.25%
Day range:
$14.64 - $15.30
52-week range:
$12.17 - $28.67
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
20.49x
P/B ratio:
1.22x
Volume:
346.4K
Avg. volume:
747.4K
1-year change:
-18.81%
Market cap:
$1B
Revenue:
$27M
EPS (TTM):
-$3.29
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BCYC
Bicycle Therapeutics PLC
|
$7M | -$0.78 | 16.38% | -23.21% | $33.36 |
|
ADAP
Adaptimmune Therapeutics PLC
|
$20.5M | -$0.18 | 4199.24% | -9.44% | $3.50 |
|
AUTL
Autolus Therapeutics PLC
|
$155K | -$0.22 | -61.82% | -46.14% | -- |
|
MREO
Mereo BioPharma Group PLC
|
-- | -$0.02 | 1109.31% | -69.36% | -- |
|
NCNA
NuCana PLC
|
-- | -$3.95 | -- | -98.11% | -- |
|
TCBP
TC BioPharm (Holdings) PLC
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BCYC
Bicycle Therapeutics PLC
|
$14.68 | $33.36 | $1B | -- | $0.00 | 0% | 20.49x |
|
ADAP
Adaptimmune Therapeutics PLC
|
$0.60 | $3.50 | $154.8M | -- | $0.00 | 0% | 0.85x |
|
AUTL
Autolus Therapeutics PLC
|
$2.29 | -- | $609.4M | -- | $0.00 | 0% | -- |
|
MREO
Mereo BioPharma Group PLC
|
$3.34 | -- | $518.2M | -- | $0.00 | 0% | -- |
|
NCNA
NuCana PLC
|
$1.20 | -- | $4.7M | -- | $0.00 | 0% | -- |
|
TCBP
TC BioPharm (Holdings) PLC
|
$0.67 | -- | $5.5M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BCYC
Bicycle Therapeutics PLC
|
-- | 1.257 | -- | 16.82x |
|
ADAP
Adaptimmune Therapeutics PLC
|
38.4% | 5.180 | 20.51% | 3.54x |
|
AUTL
Autolus Therapeutics PLC
|
-- | 4.339 | -- | 17.97x |
|
MREO
Mereo BioPharma Group PLC
|
-- | -0.254 | -- | -- |
|
NCNA
NuCana PLC
|
-- | 1.608 | -- | -- |
|
TCBP
TC BioPharm (Holdings) PLC
|
-- | -0.755 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BCYC
Bicycle Therapeutics PLC
|
-- | -$63.5M | -27.99% | -29.19% | -2026.05% | -$40.3M |
|
ADAP
Adaptimmune Therapeutics PLC
|
-- | -$14.7M | -55.22% | -67.8% | -38.33% | -$54.9M |
|
AUTL
Autolus Therapeutics PLC
|
-- | -$67.7M | -80.74% | -80.74% | -331.28% | -$86.3M |
|
MREO
Mereo BioPharma Group PLC
|
-- | -$9.1M | -- | -- | -- | -$7.5M |
|
NCNA
NuCana PLC
|
-- | -$6.6M | -- | -- | -- | -$6.4M |
|
TCBP
TC BioPharm (Holdings) PLC
|
-- | -$2.6M | -- | -- | -- | -$3.5M |
Bicycle Therapeutics PLC vs. Competitors
-
Which has Higher Returns BCYC or ADAP?
Adaptimmune Therapeutics PLC has a net margin of -1898.43% compared to Bicycle Therapeutics PLC's net margin of -43.07%. Bicycle Therapeutics PLC's return on equity of -29.19% beat Adaptimmune Therapeutics PLC's return on equity of -67.8%.
Company Gross Margin Earnings Per Share Invested Capital BCYCBicycle Therapeutics PLC-- -$0.74 $831M ADAPAdaptimmune Therapeutics PLC-- -$0.06 $129.9M -
What do Analysts Say About BCYC or ADAP?
Bicycle Therapeutics PLC has a consensus price target of $33.36, signalling upside risk potential of 127.27%. On the other hand Adaptimmune Therapeutics PLC has an analysts' consensus of $3.50 which suggests that it could grow by 274.78%. Given that Adaptimmune Therapeutics PLC has higher upside potential than Bicycle Therapeutics PLC, analysts believe Adaptimmune Therapeutics PLC is more attractive than Bicycle Therapeutics PLC.
Company Buy Ratings Hold Ratings Sell Ratings BCYCBicycle Therapeutics PLC5 3 0 ADAPAdaptimmune Therapeutics PLC4 2 0 -
Is BCYC or ADAP More Risky?
Bicycle Therapeutics PLC has a beta of 0.858, which suggesting that the stock is 14.196% less volatile than S&P 500. In comparison Adaptimmune Therapeutics PLC has a beta of 2.179, suggesting its more volatile than the S&P 500 by 117.863%.
-
Which is a Better Dividend Stock BCYC or ADAP?
Bicycle Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adaptimmune Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bicycle Therapeutics PLC pays -- of its earnings as a dividend. Adaptimmune Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BCYC or ADAP?
Bicycle Therapeutics PLC quarterly revenues are $2.7M, which are smaller than Adaptimmune Therapeutics PLC quarterly revenues of $40.9M. Bicycle Therapeutics PLC's net income of -$50.8M is lower than Adaptimmune Therapeutics PLC's net income of -$17.6M. Notably, Bicycle Therapeutics PLC's price-to-earnings ratio is -- while Adaptimmune Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bicycle Therapeutics PLC is 20.49x versus 0.85x for Adaptimmune Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BCYCBicycle Therapeutics PLC20.49x -- $2.7M -$50.8M ADAPAdaptimmune Therapeutics PLC0.85x -- $40.9M -$17.6M
-
Which has Higher Returns BCYC or AUTL?
Autolus Therapeutics PLC has a net margin of -1898.43% compared to Bicycle Therapeutics PLC's net margin of -522.15%. Bicycle Therapeutics PLC's return on equity of -29.19% beat Autolus Therapeutics PLC's return on equity of -80.74%.
Company Gross Margin Earnings Per Share Invested Capital BCYCBicycle Therapeutics PLC-- -$0.74 $831M AUTLAutolus Therapeutics PLC-- -$0.31 $582M -
What do Analysts Say About BCYC or AUTL?
Bicycle Therapeutics PLC has a consensus price target of $33.36, signalling upside risk potential of 127.27%. On the other hand Autolus Therapeutics PLC has an analysts' consensus of -- which suggests that it could grow by 356.33%. Given that Autolus Therapeutics PLC has higher upside potential than Bicycle Therapeutics PLC, analysts believe Autolus Therapeutics PLC is more attractive than Bicycle Therapeutics PLC.
Company Buy Ratings Hold Ratings Sell Ratings BCYCBicycle Therapeutics PLC5 3 0 AUTLAutolus Therapeutics PLC7 2 0 -
Is BCYC or AUTL More Risky?
Bicycle Therapeutics PLC has a beta of 0.858, which suggesting that the stock is 14.196% less volatile than S&P 500. In comparison Autolus Therapeutics PLC has a beta of 1.984, suggesting its more volatile than the S&P 500 by 98.37%.
-
Which is a Better Dividend Stock BCYC or AUTL?
Bicycle Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Autolus Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bicycle Therapeutics PLC pays -- of its earnings as a dividend. Autolus Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BCYC or AUTL?
Bicycle Therapeutics PLC quarterly revenues are $2.7M, which are smaller than Autolus Therapeutics PLC quarterly revenues of $10.1M. Bicycle Therapeutics PLC's net income of -$50.8M is higher than Autolus Therapeutics PLC's net income of -$82.1M. Notably, Bicycle Therapeutics PLC's price-to-earnings ratio is -- while Autolus Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bicycle Therapeutics PLC is 20.49x versus -- for Autolus Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BCYCBicycle Therapeutics PLC20.49x -- $2.7M -$50.8M AUTLAutolus Therapeutics PLC-- -- $10.1M -$82.1M
-
Which has Higher Returns BCYC or MREO?
Mereo BioPharma Group PLC has a net margin of -1898.43% compared to Bicycle Therapeutics PLC's net margin of --. Bicycle Therapeutics PLC's return on equity of -29.19% beat Mereo BioPharma Group PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BCYCBicycle Therapeutics PLC-- -$0.74 $831M MREOMereo BioPharma Group PLC-- -$0.10 -- -
What do Analysts Say About BCYC or MREO?
Bicycle Therapeutics PLC has a consensus price target of $33.36, signalling upside risk potential of 127.27%. On the other hand Mereo BioPharma Group PLC has an analysts' consensus of -- which suggests that it could grow by 114.45%. Given that Bicycle Therapeutics PLC has higher upside potential than Mereo BioPharma Group PLC, analysts believe Bicycle Therapeutics PLC is more attractive than Mereo BioPharma Group PLC.
Company Buy Ratings Hold Ratings Sell Ratings BCYCBicycle Therapeutics PLC5 3 0 MREOMereo BioPharma Group PLC0 0 0 -
Is BCYC or MREO More Risky?
Bicycle Therapeutics PLC has a beta of 0.858, which suggesting that the stock is 14.196% less volatile than S&P 500. In comparison Mereo BioPharma Group PLC has a beta of 0.935, suggesting its less volatile than the S&P 500 by 6.519%.
-
Which is a Better Dividend Stock BCYC or MREO?
Bicycle Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mereo BioPharma Group PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bicycle Therapeutics PLC pays -- of its earnings as a dividend. Mereo BioPharma Group PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BCYC or MREO?
Bicycle Therapeutics PLC quarterly revenues are $2.7M, which are larger than Mereo BioPharma Group PLC quarterly revenues of --. Bicycle Therapeutics PLC's net income of -$50.8M is lower than Mereo BioPharma Group PLC's net income of -$15M. Notably, Bicycle Therapeutics PLC's price-to-earnings ratio is -- while Mereo BioPharma Group PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bicycle Therapeutics PLC is 20.49x versus -- for Mereo BioPharma Group PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BCYCBicycle Therapeutics PLC20.49x -- $2.7M -$50.8M MREOMereo BioPharma Group PLC-- -- -- -$15M
-
Which has Higher Returns BCYC or NCNA?
NuCana PLC has a net margin of -1898.43% compared to Bicycle Therapeutics PLC's net margin of --. Bicycle Therapeutics PLC's return on equity of -29.19% beat NuCana PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BCYCBicycle Therapeutics PLC-- -$0.74 $831M NCNANuCana PLC-- -$2.28 -- -
What do Analysts Say About BCYC or NCNA?
Bicycle Therapeutics PLC has a consensus price target of $33.36, signalling upside risk potential of 127.27%. On the other hand NuCana PLC has an analysts' consensus of -- which suggests that it could grow by 4038.89%. Given that NuCana PLC has higher upside potential than Bicycle Therapeutics PLC, analysts believe NuCana PLC is more attractive than Bicycle Therapeutics PLC.
Company Buy Ratings Hold Ratings Sell Ratings BCYCBicycle Therapeutics PLC5 3 0 NCNANuCana PLC3 1 0 -
Is BCYC or NCNA More Risky?
Bicycle Therapeutics PLC has a beta of 0.858, which suggesting that the stock is 14.196% less volatile than S&P 500. In comparison NuCana PLC has a beta of 0.944, suggesting its less volatile than the S&P 500 by 5.593%.
-
Which is a Better Dividend Stock BCYC or NCNA?
Bicycle Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NuCana PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bicycle Therapeutics PLC pays -- of its earnings as a dividend. NuCana PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BCYC or NCNA?
Bicycle Therapeutics PLC quarterly revenues are $2.7M, which are larger than NuCana PLC quarterly revenues of --. Bicycle Therapeutics PLC's net income of -$50.8M is lower than NuCana PLC's net income of -$5.9M. Notably, Bicycle Therapeutics PLC's price-to-earnings ratio is -- while NuCana PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bicycle Therapeutics PLC is 20.49x versus -- for NuCana PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BCYCBicycle Therapeutics PLC20.49x -- $2.7M -$50.8M NCNANuCana PLC-- -- -- -$5.9M
-
Which has Higher Returns BCYC or TCBP?
TC BioPharm (Holdings) PLC has a net margin of -1898.43% compared to Bicycle Therapeutics PLC's net margin of --. Bicycle Therapeutics PLC's return on equity of -29.19% beat TC BioPharm (Holdings) PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BCYCBicycle Therapeutics PLC-- -$0.74 $831M TCBPTC BioPharm (Holdings) PLC-- -$5.07 -- -
What do Analysts Say About BCYC or TCBP?
Bicycle Therapeutics PLC has a consensus price target of $33.36, signalling upside risk potential of 127.27%. On the other hand TC BioPharm (Holdings) PLC has an analysts' consensus of -- which suggests that it could grow by 349.17%. Given that TC BioPharm (Holdings) PLC has higher upside potential than Bicycle Therapeutics PLC, analysts believe TC BioPharm (Holdings) PLC is more attractive than Bicycle Therapeutics PLC.
Company Buy Ratings Hold Ratings Sell Ratings BCYCBicycle Therapeutics PLC5 3 0 TCBPTC BioPharm (Holdings) PLC0 0 0 -
Is BCYC or TCBP More Risky?
Bicycle Therapeutics PLC has a beta of 0.858, which suggesting that the stock is 14.196% less volatile than S&P 500. In comparison TC BioPharm (Holdings) PLC has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock BCYC or TCBP?
Bicycle Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TC BioPharm (Holdings) PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bicycle Therapeutics PLC pays -- of its earnings as a dividend. TC BioPharm (Holdings) PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BCYC or TCBP?
Bicycle Therapeutics PLC quarterly revenues are $2.7M, which are larger than TC BioPharm (Holdings) PLC quarterly revenues of --. Bicycle Therapeutics PLC's net income of -$50.8M is lower than TC BioPharm (Holdings) PLC's net income of -$2.5M. Notably, Bicycle Therapeutics PLC's price-to-earnings ratio is -- while TC BioPharm (Holdings) PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bicycle Therapeutics PLC is 20.49x versus -- for TC BioPharm (Holdings) PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BCYCBicycle Therapeutics PLC20.49x -- $2.7M -$50.8M TCBPTC BioPharm (Holdings) PLC-- -- -- -$2.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 23
Quantum [QMCO] is up 4.37% over the past day.
Sell
46
NUKK alert for Dec 23
Nukkleus [NUKK] is up 8.88% over the past day.
Sell
1
IIPR alert for Dec 23
Innovative Industrial Properties [IIPR] is down 4.98% over the past day.
